PML and acute myeloid leukemia: This cutoff has since remained largely unchanged with an exception of AML with PML::RARA and AML with the core-binding factor gene translocations inv(16)/t(16;16) or t(8;21), in which the presence of such rearrangements are considered as pathognomonic for AML regardless of the blast percentage.